Future of Pharma and Ingredients Theatre

Faster by design: What’s driving the acceleration of drug development timelines?

October 29 at 15:45

Accelerated timelines are no longer the exception—they’re becoming the norm across the pharma industry. An increasing number of molecules are receiving conditional or expedited approvals, often at earlier stages of development. This trend is reshaping expectations not only for clinical progress but also for CMC, where development windows are tightening significantly. Nearly two-thirds of recent FDA novel drug approvals occurred under an accelerated pathway. In this panel discussion, industry leaders will explore the forces driving this shift.

Add to calendar